Abstract
Visceral leishmaniasis (VL) is a severe form of leishmaniasis - a disease caused by protozoan parasites and transmitted by the bite of certain species of sand fly. In VL, parasites migrate to the vital organs and bone marrow, destroying white and red blood cells. VL has been called the parasitic version of HIV/AIDs (Human immunodeficiency virus infection / acquired immunodeficiency syndrome), as it attacks the immune system. The most common form of the disease is cutaneous leishmaniasis, which causes skin lesions and often leaves the infected individual permanently disfigured. Even though the disease is treatable, current treatments are difficult to administer, too expensive, or toxic for extensive use in developing nations. Furthermore, resistance to treatment is an increasing problem, particularly in India. 90% of people with VL die if the infection is left untreated, and death can come within 2 years, significantly faster than AIDS. The search for new drugs continues, with new chemical and natural compounds. Many potential drug targets have been identified in biochemical and molecular studies, and some have been validated. Attempts to exploit these targets are in progress. This article reviews the epidemiology, clinical features, control Strategies, diagnosis and current treatment about visceral leishmaniasis.
Keywords: AIDS, Protozoan parasites, Visceral leishmaniasis.
Current Drug Delivery
Title:New Insights into the Diagnosis and Chemotheraphy for Visceral Leishmaniasis
Volume: 11 Issue: 2
Author(s): V. Dinesh Kumar, Priya Ranjan Prasad Verma and Sandeep Kumar Singh
Affiliation:
Keywords: AIDS, Protozoan parasites, Visceral leishmaniasis.
Abstract: Visceral leishmaniasis (VL) is a severe form of leishmaniasis - a disease caused by protozoan parasites and transmitted by the bite of certain species of sand fly. In VL, parasites migrate to the vital organs and bone marrow, destroying white and red blood cells. VL has been called the parasitic version of HIV/AIDs (Human immunodeficiency virus infection / acquired immunodeficiency syndrome), as it attacks the immune system. The most common form of the disease is cutaneous leishmaniasis, which causes skin lesions and often leaves the infected individual permanently disfigured. Even though the disease is treatable, current treatments are difficult to administer, too expensive, or toxic for extensive use in developing nations. Furthermore, resistance to treatment is an increasing problem, particularly in India. 90% of people with VL die if the infection is left untreated, and death can come within 2 years, significantly faster than AIDS. The search for new drugs continues, with new chemical and natural compounds. Many potential drug targets have been identified in biochemical and molecular studies, and some have been validated. Attempts to exploit these targets are in progress. This article reviews the epidemiology, clinical features, control Strategies, diagnosis and current treatment about visceral leishmaniasis.
Export Options
About this article
Cite this article as:
Kumar Dinesh V., Verma Ranjan Prasad Priya and Singh Kumar Sandeep, New Insights into the Diagnosis and Chemotheraphy for Visceral Leishmaniasis, Current Drug Delivery 2014; 11 (2) . https://dx.doi.org/10.2174/15672018113106660057
DOI https://dx.doi.org/10.2174/15672018113106660057 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Protein Tyrosine Signaling and its Potential Therapeutic Implications in Carcinogenesis
Current Pharmaceutical Design The Potential Health Benefits of Algae and Micro Algae in Medicine: A Review on Spirulina platensis
Current Nutrition & Food Science Anticancer Metallotherapeutics in Preclinical Development
Current Medicinal Chemistry Contrast Enhanced Ultrasonography for Focal Liver Lesions Characterization: Clinical Perspective
Current Medical Imaging Extracellular Vesicles in the Treatment of Parkinson’s Disease: A Review
Current Medicinal Chemistry Drug Targets in Severe Acute Respiratory Syndrome (SARS) Virus and other Coronavirus Infections
Infectious Disorders - Drug Targets Polypharmacological Properties and Therapeutic Potential of β-Caryophyllene: A Dietary Phytocannabinoid of Pharmaceutical Promise
Current Pharmaceutical Design Targeting Matrix Metalloproteinases in Inflammatory Conditions
Current Drug Targets Microsphere Based Improved Sunscreen Formulation of Ethylhexyl Methoxycinnamate
Current Drug Delivery Photodynamic Inactivation of Bacteria
Current Bioactive Compounds How Much of Familial Breast Cancer Risk is Currently Explained by the Known Genes?
Current Women`s Health Reviews Mass Spectrometry Characterization of Plant Phosphoproteins
Current Protein & Peptide Science Pioglitazone and Cancer: Angel or Demon?
Current Pharmaceutical Design Review on Patents for Ubiquitin-Proteasome Inhibitor as Medical Advance in Major Human Diseases
Recent Patents on Biomedical Engineering (Discontinued) (Phospho)lipid-based Nanosystems for Skin Administration
Current Pharmaceutical Design Calcium Antagonists: A Ready Prescription for Treating Infectious Diseases?
Current Topics in Medicinal Chemistry Reduction of Breast Cancer Relapses with Perioperative Non-Steroidal Anti-Inflammatory Drugs: New Findings and a Review
Current Medicinal Chemistry Recent Progress and Related Patents on the Applications of Bone Marrow-Derived Stem/Progenitor Cells in Regenerative Medicine and Cancer Therapies
Recent Patents on Regenerative Medicine Synergistic Interaction of Telomerase-Specific Oncolytic Virotherapy and Chemotherapeutic Agents for Human Cancer
Current Pharmaceutical Biotechnology The Ubiquitin-Proteasome Pathway and Resistance Mechanisms Developed Against the Proteasomal Inhibitors in Cancer Cells
Current Drug Targets